Potential first-to-market small molecule telomere targeting agent targets a $34 billion NSCLC treatment market Latest data in pivotal Phase 2 THIO-101 clinical trial shows median overall survival of 17.8 months CHICAGO / Jul 28, 2025 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer,... Read More

Manuscript featured in leading open-access peer-reviewed scientific journal Nucleic Acids Research CHICAGO / Jul 17, 2025 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the publication of preclinical data from its second generation ateganosine prodrugs platform in... Read More

CHICAGO / Jul 09, 2025 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced dosing of the first patient in Taiwan in the expansion phase of its THIO-101 Phase 2 trial for advanced non-small cell lung cancer (NSCLC). The trial’s entry into another continent marks a key milestone for MAIA, opening... Read More

CHICAGO / Jul 01, 2025 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced two upcoming poster presentations at the 49th Federation of European Biochemical Societies (FEBS) 2025 Congress, hosted by the Turkish Biochemical Society, to be held July 5-9, 2025, in Istanbul,... Read More

Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway CHICAGO / Jun 24, 2025 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David... Read More

Agreement to support future studies investigating the combination of ateganosine and atezolizumab for safe and effective cancer treatments CHICAGO / Jun 18, 2025 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its entry into a clinical master supply agreement with Roche for future studies... Read More

CHICAGO / Jun 10, 2025 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its participation in the upcoming BIO (Biotechnology Innovation Organization) International Convention 2025 taking place June 16-19, 2025, in Boston, Massachusetts. MAIA Chairman and CEO Vlad Vitoc, MD, MBA will deliver a... Read More

CHICAGO / Jun 05, 2025 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced a new partial response (PR) was identified in a patient after 20 months of treatment in its Phase 2 THIO-101 clinical trial evaluating ateganosine (THIO), sequenced with Regeneron’s immune... Read More

Median overall survival (OS) from ateganosine (THIO) treatment extends to 17.8 months in latest data CHICAGO / Jun 05, 2025 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical... Read More

CHICAGO / May 27, 2025 / Business Wire / This is a correction of the announcement. The number of shares and expected proceeds from the private placement have been corrected to 463,332 shares and approximately $695,000. All other aspects of the announcement remain the same. The updated release reads: MAIA BIOTECHNOLOGY ANNOUNCES PRIVATE PLACEMENT OF APPROXIMATELY $695,000 MAIA Biotechnology, Inc., (NYSE American: MAIA)... Read More

CHICAGO / May 27, 2025 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 446,332 shares of common stock at a purchase price of $1.50 per share, in a private placement to accredited... Read More

CHICAGO / May 15, 2025 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract about the efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 30 to... Read More

CHICAGO / May 14, 2025 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that two of the Company’s independent directors, Stan V. Smith, Ph.D. and Ramiro Guerrero, JD, LL.M., purchased common stock and warrants in the Company’s private placement offering which closed on... Read More

This is a correction of the announcement. The initial exercise date and term of the warrants purchased in the private placement have been corrected to one year following issuance and have a term of six years from the initial issuance date. All other aspects of the announcement remain the same. CHICAGO / May 05, 2025 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage... Read More

CHICAGO / May 05, 2025 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 719,999 shares of common stock at a purchase price of $1.50 per share, in a private placement to accredited... Read More

Lead compound THIO (ateganosine) is the only clinical-stage telomere-targeting anticancer agent throughout the field of cancer discovery Potential FDA filings in 2026 for accelerated approval from THIO-101 and early full approval from THIO-104 Full Shareholder Letter available in Investors section of MAIA’s corporate website CHICAGO / Apr 01, 2025 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA” or... Read More

Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC) CHICAGO / Mar 25, 2025 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was... Read More

Novel THIO dimer shows promise as a new compound with a dual mechanism of action for enhancing standard cancer treatments and overcoming resistance CHICAGO / Mar 20, 2025 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announces the publication of preclinical data for its lead... Read More

Nonproprietary drug name approval marks essential step in FDA approval process CHICAGO / Mar 19, 2025 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the United States Adopted Names (USAN) Council has approved “ateganosine” as the nonproprietary (generic) name for its lead... Read More

CHICAGO / Feb 27, 2025 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced plans to initiate a Phase 3 pivotal trial in 2025, named THIO-104, to evaluate the efficacy of THIO administered in sequence with a checkpoint inhibitor (CPI) in third-line non-small cell lung cancer (NSCLC)... Read More

Expansion study to enroll patients in the U.S. and select countries in Europe and Asia Multiple milestones attainable for 2025 CHICAGO / Feb 26, 2025 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA,” the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the trial design for the expansion of its THIO-101 pivotal Phase 2 trial in... Read More

CHICAGO / Feb 24, 2025 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 952,300 shares of common stock at a purchase price of $1.50 per share, in a non-brokered private placement to... Read More

CHICAGO / Feb 18, 2025 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,810,000 shares of common stock at a purchase price of $1.50 per share, in a private placement to accredited... Read More

Median overall survival (OS) from THIO treatment extends to 16.9 months Newest data strengthens regulatory strategy CHICAGO / Feb 04, 2025 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead... Read More

CEO to detail THIO-101 expansion trial and upcoming trials in multiple indications CHICAGO / Jan 10, 2025 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chief Executive Officer Vlad Vitoc, M.D. will present at the Biotech Showcase™ 2025 investor conference taking place in... Read More

Phase 2 pivotal trials to evaluate efficacy of THIO in combination with BeiGene’s checkpoint inhibitor (CPI) tislelizumab CHICAGO--( BUSINESS WIRE )-- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into a clinical supply agreement with global oncology company BeiGene to... Read More

CHICAGO / Dec 19, 2024 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that two of the Company’s independent directors, Ramiro Guerrero, JD, LL.M. and Stan V. Smith, Ph.D., purchased MAIA’s common stock and warrants in each of the Company’s recent private placement closings... Read More

CHICAGO / Dec 16, 2024 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the FDA has designated THIO for the treatment of pediatric-type diffuse high-grade gliomas (PDHGG) as a drug for a “rare pediatric disease.” “THIO is a versatile anti-cancer agent that has demonstrated... Read More

CHICAGO / Dec 09, 2024 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 507,364 shares of common stock at a purchase price of $1.872 per share, in a private placement to accredited... Read More

Expansion of 2021 clinical supply agreement for Phase 2 clinical trial Next stage of trial to further assess efficacy of THIO in third line non-small cell lung cancer patients MAIA expects new patient enrollment to begin soon in the expansion of THIO-101 CHICAGO / Dec 03, 2024 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing... Read More

CHICAGO / Nov 07, 2024 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Stan V. Smith, Ph.D. made an individual purchase of 100,000 shares of MAIA’s common stock, and warrants to purchase 100,000 shares, of MAIA’s common stock for an aggregate purchase... Read More

Late breaking abstract to provide new updates from THIO-101 Phase 2 clinical trial in non-small cell lung cancer (NSCLC) Poster to highlight long-term therapeutic benefits of THIO sequenced with cemiplimab beyond treatment cessation CHICAGO / Nov 05, 2024 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies... Read More

CHICAGO / Oct 28, 2024 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,079,784 shares of common stock at a purchase price of $2.259 per share, in a private placement to accredited... Read More

MAIA seeks to advance two new THIO-derived telomere-targeting molecules to clinical trials CHICAGO / Oct 15, 2024 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract related to the company’s second generation of proprietary telomere-targeting THIO prodrugs has been... Read More

16 patients surpassed 12-month survival follow-up THIO's substantial survival benefit in third line surpasses comparable standard-of-care overall survival of 5.8 months Median survival follow-up in third line was 10.6 months Treatment with THIO followed by Libtayo® has been generally well-tolerated to date CHICAGO / Sep 10, 2024 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a... Read More

THIO followed by cemiplimab shown to be well tolerated throughout trial, with far lower toxicity compared to standard of care treatments 6 patients on trial regimen for more than 12 months have completed up to 21 cycles, with treatment ongoing CHICAGO / Jul 23, 2024 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted... Read More

FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment CHICAGO / Jun 07, 2024 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage company developing telomere-targeting immunotherapies for cancer, today announced the validation of clinical and regulatory pathways for viable therapies leveraging the cell’s telomeric... Read More

New science for cancer therapy drives powerful value proposition Exceptional measures of efficacy by lead drug THIO in Phase 2 clinical trial Funding of more than $12M year-to-date, including $7.4 million in Q2’24 so far Secured continued insider investment through independent board members’ participation in private placement equity financings Newest data shows THIO’s strong outperformance against standard-of-care treatments... Read More

THIO’s favorable disease control and overall response rates exceed reported standard-of-care data in third line treatment CHICAGO / Jun 04, 2024 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced new efficacy data from its Phase 2 THIO-101 clinical trial evaluating THIO sequenced... Read More

CHICAGO / May 17, 2024 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, announced its participation in the upcoming BIO International Convention taking place June 3-6, 2024, in San Diego, California. The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem... Read More

Poster to present new efficacy data from Phase 2 THIO-101 trial in non-small cell lung cancer (NSCLC) CHICAGO / May 16, 2024 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract about its Phase 2 THIO-101 clinical trial named “ A phase 2, multicenter, open-label,... Read More

Original seed investor has remained top MAIA stockholder CHICAGO / Apr 30, 2024 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Ms. Adelina Louie Ngar Yee made an individual purchase of 19,665 shares, and warrants for 19,665 shares, of MAIA’s common... Read More

Dr. Smith has participated in every MAIA funding round CHICAGO / Apr 29, 2024 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Stan V. Smith, Ph.D. made an individual purchase of 147,492 shares, and warrants for 147,492 shares, of MAIA’s common stock... Read More

CHICAGO / Apr 23, 2024 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 494,096 shares of common stock at a purchase price of $2.034 per share, in a private placement to accredited... Read More

CHICAGO / Apr 05, 2024 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chairman and Chief Executive Officer Vlad Vitoc, M.D. will present at two investor conferences during the month of April: the 14th Annual LD Micro Invitational taking place April 8-9, 2024, in New York... Read More

Company recognizes significant support by board members in recent private placement CHICAGO / Mar 28, 2024 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent directors Cristian Luput and Ramiro Guerrero, J.D, LL.M. made individual purchases of 69,282 and 6,928... Read More

Five independent members of MAIA’s Board of Directors purchased shares in the offering CHICAGO / Mar 26, 2024 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Ms. Adelina Louie Ngar Yee made an individual purchase of 170,940 shares of the Company’s... Read More

CHICAGO / Mar 26, 2024 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 578,643 shares of common stock at a purchase price of $2.295 per share, in a private placement to accredited... Read More

Dr. Smith has participated in every MAIA funding round CHICAGO / Mar 22, 2024 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA,” the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Mr. Stan V. Smith, Ph.D. made an individual purchase of 170,940 shares of the Company’s common stock as part of the Company’s... Read More

Acclaimed academic researcher has led 40+ multicenter phase 2 and phase 3 clinical studies CHICAGO / Mar 21, 2024 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment... Read More

CHICAGO / Mar 07, 2024 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced its participation in the 36th Annual ROTH Conference being held March 17-19, 2024 in Dana Point, California. Chief Executive Offer Vlad Vitoc, M.D. will host one-on-one meetings with institutional investors... Read More

THIO and ionizing radiation combination shown to significantly decrease cell proliferation and produce potent anticancer effects in highly aggressive, treatment-resistant childhood brain cancer CHICAGO / Mar 06, 2024 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Dr.... Read More

Combination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, third-line non-small cell lung cancer (NSCLC) ORR of 38% significantly exceeds standard of care ORR in NSCLC third-line in patients without a targetable mutation who progressed on checkpoint inhibitors and chemotherapy CHICAGO / Mar 06, 2024 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA”, the... Read More

THIO-101 Phase 2 trial nears completion with survival and response data forthcoming; exploration of multiple cancer indications and next-generation molecules continues. Shareholder Letter available in Investor Relations section of MAIA’s corporate website. CHICAGO / Mar 05, 2024 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing... Read More

THIO treatment leads to profound activation of innate and adaptive anti-tumor responses THIO depletes cancer initiating cells (CICs) and thus diminishes tumor initiation and metastasis-forming potential in various in vivo models THIO previously awarded orphan drug designation (ODD) by FDA for small cell lung cancer (SCLC) treatment CHICAGO / Feb 07, 2024 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA)... Read More

New patent would extend coverage and expand potential value of MAIA’s telomere-targeting platform globally CHICAGO / Jan 24, 2024 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the World Intellectual Property Organization (WIPO) has published MAIA’s global Patent... Read More

Lead candidate THIO maintains unprecedented disease control rates in Phase 2 non-small cell lung cancer (NSCLC) clinical trial Multiple clinical milestones ahead for THIO-101 Phase 2 trial Company enters 2024 with robust clinical pipeline in multiple hard-to-treat cancer indications CHICAGO / Jan 17, 2024 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage... Read More

CHICAGO / Jan 05, 2024 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, today announced its participation in the Biotech Showcase ™ 2024 investor conference being held January 8-10, 2024, in San Francisco, California. Chairman and Chief Executive Officer Vlad Vitoc, MD, MBA will... Read More

Selected dose shows unprecedented disease control and overall response rates in a NSCLC clinical trial CHICAGO / Dec 19, 2023 / Business Wire / MAIA Biotechnology, Inc. , (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, today announced dose selection for THIO-101, a Phase 2 clinical trial evaluating its lead asset, THIO, in... Read More

CHICAGO / Nov 17, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, today announced that it has closed its previously announced registered direct offering for the issuance and sale of an aggregate of 2,424,243 of its shares of common stock at a purchase price of $1.65 per share.... Read More

CHICAGO / Nov 15, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,424,243 of its shares of common stock at a purchase price of $1.65 per share in a registered direct... Read More

Third orphan drug designation (ODD) granted to THIO by the FDA; drug also holds ODDs for hepatocellular carcinoma and small cell lung cancer Benefits include 7 years of U.S. market exclusivity after drug approval and tax credits for qualified clinical testing Expected glioblastoma market growth from $2.2 billion to $3.2 billion globally in the next three years CHICAGO / Nov 10, 2023 / Business Wire / MAIA Biotechnology, Inc.... Read More

Substantial THIO program progress including unprecedented disease control rate (DCR) of 100% in second-line non-small cell lung cancer (NSCLC) Key THIO findings in gliomas, pediatric brain cancer, and second generation THIO-derived cancer therapies Strong pace of enrollment in THIO-101 Phase 2 trial exceeds average enrollment pace in similar NSCLC trials CHICAGO / Nov 07, 2023 / Business Wire / MAIA Biotechnology, Inc. ,... Read More

Study results warrant further in vivo in-depth investigation of THIO conjugates as second generation cancer therapies CHICAGO / Oct 30, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced positive results from an investigational new drug-enabling study of the Company’s second-generation telomere-targeting... Read More

Unprecedented disease control rate (DCR) of 100% in second-line of treatment far surpasses standard of care (SoC) DCR of 53-64% DCR is far stronger than overall response rate (ORR) in predicting overall survival benefit, as shown in recent meta-analysis of 74 clinical trials worldwide 1 CHICAGO / Oct 24, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing... Read More

CHICAGO / Oct 19, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced that preliminary safety and efficacy data from its ongoing Phase 2 clinical trial, THIO-101, was accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held in Madrid, Spain, October 20-24,... Read More

CHICAGO / Oct 17, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, announced its participation in the International Biochemistry Congress 2023, organized by the Turkish Biochemical Society, which will be held in Turkey from October 29 to November 1, 2023. On October 30 th , MAIA’s Chief Scientific Officer Sergei Gryaznov,... Read More

Treatment demonstrates decreased cancer cell proliferation and increased tumor sensitivity to ionizing radiation CHICAGO / Oct 12, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, announced that study data shows THIO’s potent anticancer activity in Diffuse Intrinsic Pontine Glioma (DIPG), one of the most aggressive tumors... Read More

49 patients dosed to date; 37 have completed at least 1 post baseline assessment THIO-101 enrollment pace currently exceeds average for similar NSCLC trials CHICAGO / Oct 10, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, announced today that 49 patients have been dosed in MAIA’s Phase 2 clinical trial, THIO-101,... Read More

CHICAGO / Oct 10, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced that its lead asset THIO showed highly potent anticancer activity in gliomas, an aggressive type of brain tumor that originates from glial cells. THIO’s novel dual mechanism of action - direct telomere targeting and immune system... Read More

THIO to be Evaluated in the U.S. as Part of Current THIO-101 Global Phase 2 Clinical Trial CHICAGO / Oct 03, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for THIO to be evaluated in the U.S. as... Read More

CHICAGO / Sep 28, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $800,000 of its Class A common stock through September 2024. “This share repurchase program demonstrates the confidence we have in our... Read More

Filed second provisional new composition of matter patent application for MAIA’s third entirely home-grown telomere-targeting molecule Reported 35 patients enrolled as of July 2023 in THIO-101 Phase 2 Trial First 2 patients dosed with THIO continue to be without documented disease progression for 12.2 and 11.5 months, and remarkably without any new anti-cancer treatment 10.2 and 8.5 months after concluding treatment with... Read More

Of the first 11 patients with post-baseline scans, 9 met the disease control primary endpoint at first response assessment. CHICAGO / Jul 11, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) today announced updates on disease control data in the Part A safety lead-in of its ongoing THIO-101 phase 2 trial, evaluating THIO in sequential combination with cemiplimab in patients with advanced Non-Small Cell... Read More

First 2 patients dosed with THIO continue to be without documented progression for 12.2 and 11.5 months and remarkably without any new anti-cancer treatment 10.2 and 8.5 months after concluding treatment with THIO. CHICAGO / Jul 10, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) today announced updates on preliminary survival data in the Part A safety lead-in of its ongoing THIO-101 phase 2 trial,... Read More

CHICAGO / Jun 20, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) announced today that 29 patients have been dosed in MAIA’s Phase 2 clinical trial, THIO-101, evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC). With the addition of sites in Hungary, Poland, and Bulgaria in March 2023, THIO-101 has rapidly increased the number of patients enrolled and dosed with THIO. Thirteen... Read More

Filed provisional new composition of matter patent application for MAIA’s third entirely home-grown telomere-targeting molecule CHICAGO / Jun 07, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) today announced its second broad provisional patent application covering the composition of matter for a new... Read More

Reported positive topline data from the completed Part A safety lead-in of the THIO-101 Phase 2 go-to-market trial in advanced Non-Small Cell Lung Cancer (NSCLC) and commenced recruitment in Part B randomized efficacy/dose selection Outlined preliminary safety data from Part A survival safety data from THIO-101 with first two enrolled patients alive after approximately 10 and 9 months post treatment initiation, respectively... Read More

NEW YORK / Apr 27, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the closing of its previously announced public offering of 2,555,500 shares of its common stock at a public offering price of $2.25 per share, for gross proceeds of approximately $5.75 million, before deducting underwriting... Read More

CHICAGO / Apr 20, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) today announced preliminary survival data in the Part A safety lead-in of its ongoing phase 2 trial, THIO-101 evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC). The first 2 patients enrolled in Part A of the study continue to be alive, approximately 10 and 9 months respectively, from treatment initiation. Both... Read More

Study showed THIO with complete and durable responses in Hepatocellular Carcinoma (HCC), or the dominate histology in primary liver cancer (90%), in vivo models When combined with immunotherapy checkpoint inhibitor (CPI), duration of response was further potentiated Administration of THIO alone and in combination with CPI generated anti-cancer immune memory Upon rechallenge with two times more cancer cells and no additional... Read More

CHICAGO / Apr 12, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) today announced that it will present a poster that will feature the design of its ongoing Phase 2 clinical trial, THIO-101 evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC). The poster will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, which is taking place in-person at... Read More

CHICAGO / Apr 11, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) today announced positive topline data from the completed Part A safety lead-in of the Company’s THIO-101 Phase 2 go-to-market trial in advanced Non-Small Cell Lung Cancer (NSCLC) and has commenced recruitment in Part B randomized efficacy/dose selection. Topline data from Part A demonstrated that MAIA’s telomere-targeting agent, THIO,... Read More

CHICAGO / Mar 13, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) announced today the Company has no exposure to Silicon Valley Bank (“SVB”). The Company is aware that the Federal Deposit Insurance Corp. has taken control of SVB due to liquidity concerns. The Company confirms it does not hold any deposits or investments at SVB, as well as at Silvergate Bank, or Signature Bank. MAIA’s cash is managed... Read More

CHICAGO / Mar 07, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) announced today that the first two patients have been dosed in Europe in MAIA’s Phase 2 clinical trial, THIO-101 evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC). Following regulatory clearances in Hungary, Poland, and Bulgaria, five clinical sites have been activated in these three European countries. The... Read More

CHICAGO / Feb 13, 2023 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA ) announced today it intends to initiate its second Phase 2 go-to-market trial evaluating THIO, the world’s first telomere-targeting agent, in patients with four cancer indications. The FDA has awarded MAIA’s lead anti-cancer agent THIO two Orphan Drug Designations, based on the preclinical efficacy data, for liver (hepatocellular... Read More

Progressing next generation of telomere-targeting candidates through proof of concept studies with promising anti-cancer activity Filed provisional new composition of matter patent during fourth quarter 2022 MAIA Biotechnology, Inc. (NYSE American: MAIA) announced today the advancement of its Telomere-Targeting Molecule Program (“Project T3”). MAIA is designing and evaluating multiple telomere-targeting compounds designed to... Read More

MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”) announced today that the management team will participate in the four upcoming investor conferences as follows: Biotech Showcase: The Investor Conference for Innovators will be held in-person in San Francisco from January 9-11, and virtually from January 18-19. The MAIA team will host investor meetings and is scheduled to present on Monday, January 9 at... Read More

CHICAGO--( BUSINESS WIRE )-- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”) today announced that it completed a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the planned U.S. expansion of the THIO-101 Phase 2 trial evaluating THIO, an investigational telomere-targeting agent, in patients with advanced non-small cell lung cancer (NSCLC). MAIA... Read More

Clinical trial evaluating MAIA Biotechnology’s lead therapeutic candidate in non-small cell lung cancer patients CHICAGO--( BUSINESS WIRE )-- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”), announced today that regulatory authorities in three European countries, Hungary, Poland, and Bulgaria, have approved the implementation of THIO-101, MAIA’s Phase 2 clinical trial evaluating its lead therapeutic... Read More